Liraglutide Causing Pancreatitis in an Indian Obese Female: A Case Report and Review of the Literature

Published May 15, 2026Current drug safety

Pancreatitis Possibly Linked to Liraglutide in an Obese Indian Woman: A Case Report and Literature Review

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Page updated May 16, 2026

Abstract

A 42-year-old woman developed acute pancreatitis after one month of liraglutide treatment for obesity.

The patient experienced severe abdominal pain and vomiting three days prior to presentation.
Laboratory tests indicated significantly elevated serum amylase and lipase levels.
Imaging confirmed acute interstitial edematous pancreatitis with no alternative causes identified.
Discontinuation of liraglutide and supportive care led to full recovery within five days.
A review of the literature identified 12 cases of liraglutide-induced acute pancreatitis, suggesting a need for caution among clinicians.

AI simplified

INTRODUCTION: Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is commonly prescribed for obesity and type 2 diabetes mellitus (T2DM). While its metabolic benefits are well-established, rare cases of acute pancreatitis (AP) have raised concerns about drug safety. Despite regulatory warnings from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), causality remains debated due to confounding factors and limited human data.

CASE PRESENTATION: We, herein, report the case of a 42-year-old Indian female with obesity (BMI 32.5 kg/m²) who developed acute-onset severe epigastric pain and vomiting three days prior to presentation. She had been using liraglutide 0.6 mg/day for one month for weight management. Laboratory investigations revealed significantly elevated serum amylase and lipase, while abdominal ultrasonography and contrast-enhanced CT scan confirmed acute interstitial edematous pancreatitis. No other common etiologies were identified. Prompt discontinuation of liraglutide and supportive care resulted in full clinical recovery within five days.

CONCLUSION: A systematic literature search yielded 10 relevant case reports encompassing 11 cases of liraglutide-induced acute pancreatitis, with our case bringing the total to 12. These cases showed a slight male predominance and favorable outcomes with conservative treatment. Our report thus highlights the need for clinician vigilance and risk-benefit assessment when prescribing liraglutide, emphasizing early drug cessation upon suspicion of pancreatitis.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (HTML) ↗View full text ↗

Liraglutide Causing Pancreatitis in an Indian Obese Female: A Case Report and Review of the Literature

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief